Literature DB >> 8889266

Comparison of the central nervous system effects produced by six H1-receptor antagonists.

F E Simons1, T G Fraser, J D Reggin, K J Simons.   

Abstract

BACKGROUND: A comprehensive comparative study of the central nervous system (CNS) properties of newer H1-receptor antagonist is needed.
OBJECTIVE: Our objective was to investigate the central nervous system effects of a single manufacturer's recommended dose of six H1-receptor antagonists, using appropriate controls.
METHODS: Fifteen healthy subjects received astemizole 10 mg, cetirizine 10 mg, ketotifen 2 mg, loratadine 10 mg, terfenadine 60 mg, diphenhydramine 50 mg or placebo. Before and 2-2.5 h after dosing, cognitive function was assessed using the P300-event-related potential, somnolence was assessed using a subjective score, and histamine skin tests were performed.
RESULTS: In rank order from least to greatest effect on the P300 latency, the medications were: terfenadine, placebo, cetirizine, ketotifen, loratadine, astemizole and diphenhydramine. Only diphenhydramine increased the P300 latency significantly compared with baseline and placebo. Subjective somnolence was significantly greater than baseline and placebo after cetirizine, ketotifen and diphenhydramine. All the H1-receptor antagonists suppressed the histamine induced weal significantly compared with baseline.
CONCLUSIONS: The H1-receptor antagonist tested affected cognitive functioning and somnolence to different extents, although all produced satisfactory peripheral H1-blockade.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8889266

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN: 0954-7894            Impact factor:   5.018


  13 in total

Review 1.  Sedation, cognition, and antihistamines.

Authors:  Julie C Qidwai; Ginger S Watson; John M Weiler
Journal:  Curr Allergy Asthma Rep       Date:  2002-05       Impact factor: 4.806

Review 2.  New insights into the second generation antihistamines.

Authors:  G M Walsh; L Annunziato; N Frossard; K Knol; S Levander; J M Nicolas; M Taglialatela; M D Tharp; J P Tillement; H Timmerman
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 3.  The economic burden of allergic rhinitis: a critical evaluation of the literature.

Authors:  Shelby D Reed; Todd A Lee; Douglas C McCrory
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

Review 4.  Improving the prediction of the brain disposition for orally administered drugs using BDDCS.

Authors:  Fabio Broccatelli; Caroline A Larregieu; Gabriele Cruciani; Tudor I Oprea; Leslie Z Benet
Journal:  Adv Drug Deliv Rev       Date:  2011-12-21       Impact factor: 15.470

5.  Comparison of the risk of drowsiness and sedation between levocetirizine and desloratadine: a prescription-event monitoring study in England.

Authors:  Deborah Layton; Lynda Wilton; Andrew Boshier; Victoria Cornelius; Scott Harris; Saad A W Shakir
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

6.  Brain histamine H receptor occupancy of orally administered antihistamines measured by positron emission tomography with (11)C-doxepin in a placebo-controlled crossover study design in healthy subjects: a comparison of olopatadine and ketotifen.

Authors:  Manabu Tashiro; Hideki Mochizuki; Yumiko Sakurada; Kenji Ishii; Keiichi Oda; Yuichi Kimura; Toru Sasaki; Kiichi Ishiwata; Kazuhiko Yanai
Journal:  Br J Clin Pharmacol       Date:  2006-01       Impact factor: 4.335

7.  Second-generation antihistamines: a comparative review.

Authors:  J W Slater; A D Zechnich; D G Haxby
Journal:  Drugs       Date:  1999-01       Impact factor: 9.546

Review 8.  Second-generation antihistamines: actions and efficacy in the management of allergic disorders.

Authors:  Larry K Golightly; Leon S Greos
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 9.  Selecting the optimal oral antihistamine for patients with allergic rhinitis.

Authors:  Jeffrey M Lehman; Michael S Blaiss
Journal:  Drugs       Date:  2006       Impact factor: 9.546

10.  Cetirizine: a review of its use in allergic disorders.

Authors:  Monique P Curran; Lesley J Scott; Caroline M Perry
Journal:  Drugs       Date:  2004       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.